Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma

Leukemia Research

Volumn 32, Issue 10, 2008, Pages 1499-1504

  Kádár, Katalin ^a   Kovács, Margit ^b   Karádi, István ^b   Melegh, Béla ^c   Pocsai, Zsuzsa ^d   Mikala, Gábor ^e   Tordai, Attila ^e   Szilágyi, Ágnes ^b   Ádány, Róza ^d   Füst, George ^b   Várkonyi, Judit ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

^d Medical and Health Science Centre   (Hungary)

^e NATIONAL MEDICAL CENTER   (Hungary)

Author keywords

8.1 ancestral haplotype; Ancestral haplotype; Heat shock protein 70; Lymphotoxin alpha; Multiple myeloma; RAGE; SNP; TNF alpha

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HEAT SHOCK PROTEIN 70; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROMOTER REGION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44749094021     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.03.001     Document Type: Article

References (34)

1. Shapiro-Shelef M., and Calame K. Plasma cell differentiation and multiple myeloma. Curr Opin Immunol 16 (2004) 226-234
2. Jourdan M., Tarte K., Legouffe E., Brochier J., Rossi J.F., and Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 10 (1999) 65-70
3. Borset M., Waage A., Brekke O.L., and Helseth E. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol 53 (1994) 31-37
4. Borset M., Medvedev A.E., Sundan A., and Espevik T. The role of the two TNF receptors in proliferation, NF-kappa B activation and discrimination between TNF and LT alpha signalling in the human myeloma cell line OH-2. Cytokine 8 (1996) 430-438
5. Jurisic V., and Colovic M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol 19 (2002) 133-139
6. Locksley R.M., Killeen N., Lenardo M.J., and The T.N.F. TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2001) 487-501
7. Nedwin G.E., Naylor S.L., Sakaguchi A.Y., Smith D., Jarrett-Nedwin J., Pennica D., et al. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res 13 (1985) 6361-6373
8. Nedospasov S.A., Udalova I.A., Kuprash D.V., and Turetskaya R.L. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-beta) gene. J Immunol 147 (1991) 1053-1059
9. Messer G., Spengler U., Jung M.C., Honold G., Blomer K., Pape G.R., et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173 (1991) 209-219
10. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., and Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94 (1997) 3195-3199
11. Dawkins R.L., Christiansen F.T., Kay P.H., Garlepp M., McCluskey J., Hollingsworth P.N., et al. Disease associations with complotypes, supratypes and haplotypes. Immunol Rev 70 (1983) 1-22
12. Candore G., Lio D., Colonna Romano G., and Caruso C. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev 1 (2002) 29-35
13. Candore G., Modica M.A., Lio D., Colonna-Romano G., Listi F., Grimaldi M.P., et al. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: a genetically determined defect of C4 influences immunological parameters of healthy carriers of the haplotype. Biomed Pharmacother 57 (2003) 274-277
14. Aly T.A., Ide A., Jahromi M.M., Barker J.M., Fernando M.S., Babu S.R., et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci USA 103 (2006) 14074-14079
15. Smerdel-Ramoya A., Finholt C., Lilleby V., Gilboe I.M., Harbo H.F., Maslinski S., et al. Systemic lupus erythematosus and the extended major histocompatibility complex-evidence for several predisposing loci. Rheumatology (Oxford) 44 (2005) 1368-1373
16. McHugh N.J., Owen P., Cox B., Dunphy J., and Welsh K. MHC class II, tumour necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus. Ann Rheum Dis 65 (2006) 488-494
17. Davies F.E., Rollinson S.J., Rawstron A.C., Roman E., Richards S., Drayson M., et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 18 (2000) 2843-2851
18. Neben K., Mytilineos J., Moehler T.M., Preiss A., Kraemer A., Ho A.D., et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 100 (2002) 2263-2265
19. Zheng C., Huang D.R., Bergenbrant S., Sundblad A., Osterborg A., Bjorkholm M., et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 109 (2000) 39-45
20. Iakupova E.V., Grinchuk O.V., Kalimullina D., Bakirov B.A., Galimova R.R., Makarova O.V., et al. Molecular genetic analysis of the interleukin 6 and tumor necrosis factor alpha gene polymorphisms in multiple myeloma. Mol Biol (Mosk) 37 (2003) 420-424
21. Morgan G.J., Adamson P.J., Mensah F.K., Spink C.F., Law G.R., Keen L.J., et al. Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol 129 (2005) 358-365
22. Durie B.G., and Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36 (1975) 842-854
23. Szeles G., Voko Z., Jenei T., Kardos L., Pocsai Z., Bajtay A., et al. A preliminary evaluation of a health monitoring programme in Hungary. Eur J Public Health 15 (2005) 26-32
24. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
25. Day C.P., Grove J., Daly A.K., Stewart M.W., Avery P.J., and Walker M. Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 41 (1998) 430-434
26. Seidemann K., Zimmermann M., Book M., Meyer U., Burkhardt B., Welte K., et al. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Munster Trial NHL-BFM 95. J Clin Oncol 23 (2005) 8414-8421
27. Vargas-Alarcon G., Londono J.D., Hernandez-Pacheco G., Gamboa R., Castillo E., Pacheco-Tena C., et al. Heat shock protein 70 gene polymorphisms in Mexican patients with spondyloarthropathies. Ann Rheum Dis 61 (2002) 48-51
28. Hudson B.I., Stickland M.H., Futers T.S., and Grant P.J. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50 (2001) 1505-1511
29. Brown E.E., Lan Q., Zheng T., Zhang Y., Wang S.S., Hoar-Zahm S., et al. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 120 (2007) 2715-2722
30. Harcos P., Laki J., Kiszel P., Szeplaki Z., Szolnoki Z., Kovacs M., et al. Decreased frequency of the TNF2 allele of TNF-alpha -308 promoter polymorphism is associated with lacunar infarction. Cytokine 33 (2006) 100-105
31. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12 (2007) 115-130
32. Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.J., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12 (2007) 131-144
33. Candore G., Balistreri C.R., Campagna A.M., Colombo A., Cuppari I., Di-Carlo D., et al. Genetic control of immune response in carriers of ancestral haplotype 8.1: the study of chemotaxis. Ann N Y Acad Sci 1089 (2006) 509-515
34. Toth E.K., Kocsis J., Madaras B., Biro A., Pocsai Z., Fust G., et al. The 8.1 ancestral MHC haplotype is strongly associated with colorectal cancer risk. Int J Cancer 15 (2007) 1744-1748